Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies

Nancy Haigwood, David C. Montefiori, William F. Sutton, Janela McClure, Andrew J. Watson, Gerald Voss, Vanessa M. Hirsch, Barbra A. Richardson, Norman L. Letvin, Shiu Lok Hu, Philip R. Johnson

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Passively transferred neutralizing antibodies can block lentivirus infection, but their role in postexposure prophylaxis is poorly understood. In this nonhuman-primate study, the effects of short-term antibody therapy on 5-year disease progression, virus load, and host immunity were explored. We reported previously that postinfection passive treatment with polyclonal immune globulin with high neutralizing titers against SIVsmE660 (SIVIG) significantly improved the 67-week health of SIVsmE660-infected Macaca mulatta macaques. Four of six treated macaques maintained low or undetectable levels of virus in plasma, compared with one of ten controls, while two rapid progressors controlled viremia only as long as the SIVIG was present. SIVIG treatment delayed the de novo production of envelope (Env)-specific antibodies by 8 weeks (13). We show here that differences in disease progression were also significant at 5 years postinfection, excluding rapid progressors (P = 0.05). Macaques that maintained ≪103 virus particles per ml of plasma and ≪30 infectious virus particles per 106 mononuclear cells from peripheral blood and lymph nodes had delayed disease onset. All macaques that survived beyond 18 months had measurable Gag-specific CD8+ cytotoxic T cells, regardless of treatment. Humoral immunity in survivors beyond 20 weeks was strikingly different in the SIVIG and control groups. Despite a delay in Env-specific binding antibodies, de novo production of neutralizing antibodies was significantly accelerated in SIVIG-treated macaques. Titers of de novo neutralizing antibodies at week 12 were comparable to levels achieved in controls only by week 32 or later. Acceleration of de novo simian immunodeficiency virus immunity in the presence of passively transferred neutralizing antibodies is a novel finding with implications for postexposure prophylaxis and vaccines.

Original languageEnglish (US)
Pages (from-to)5983-5995
Number of pages13
JournalJournal of Virology
Volume78
Issue number11
DOIs
StatePublished - Jun 2004
Externally publishedYes

Fingerprint

Simian immunodeficiency virus
Simian Immunodeficiency Virus
Passive Immunization
immunotherapy
Macaca
Neutralizing Antibodies
neutralizing antibodies
virion
disease course
Virion
antibodies
Disease Progression
Antibodies
Immunity
disease control
Lentivirus Infections
immunity
Viruses
Lentivirus
Viremia

ASJC Scopus subject areas

  • Immunology

Cite this

Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies. / Haigwood, Nancy; Montefiori, David C.; Sutton, William F.; McClure, Janela; Watson, Andrew J.; Voss, Gerald; Hirsch, Vanessa M.; Richardson, Barbra A.; Letvin, Norman L.; Hu, Shiu Lok; Johnson, Philip R.

In: Journal of Virology, Vol. 78, No. 11, 06.2004, p. 5983-5995.

Research output: Contribution to journalArticle

Haigwood, N, Montefiori, DC, Sutton, WF, McClure, J, Watson, AJ, Voss, G, Hirsch, VM, Richardson, BA, Letvin, NL, Hu, SL & Johnson, PR 2004, 'Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies', Journal of Virology, vol. 78, no. 11, pp. 5983-5995. https://doi.org/10.1128/JVI.78.11.5983-5995.2004
Haigwood, Nancy ; Montefiori, David C. ; Sutton, William F. ; McClure, Janela ; Watson, Andrew J. ; Voss, Gerald ; Hirsch, Vanessa M. ; Richardson, Barbra A. ; Letvin, Norman L. ; Hu, Shiu Lok ; Johnson, Philip R. / Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies. In: Journal of Virology. 2004 ; Vol. 78, No. 11. pp. 5983-5995.
@article{813f8849f31843b79b71fc294904989d,
title = "Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies",
abstract = "Passively transferred neutralizing antibodies can block lentivirus infection, but their role in postexposure prophylaxis is poorly understood. In this nonhuman-primate study, the effects of short-term antibody therapy on 5-year disease progression, virus load, and host immunity were explored. We reported previously that postinfection passive treatment with polyclonal immune globulin with high neutralizing titers against SIVsmE660 (SIVIG) significantly improved the 67-week health of SIVsmE660-infected Macaca mulatta macaques. Four of six treated macaques maintained low or undetectable levels of virus in plasma, compared with one of ten controls, while two rapid progressors controlled viremia only as long as the SIVIG was present. SIVIG treatment delayed the de novo production of envelope (Env)-specific antibodies by 8 weeks (13). We show here that differences in disease progression were also significant at 5 years postinfection, excluding rapid progressors (P = 0.05). Macaques that maintained ≪103 virus particles per ml of plasma and ≪30 infectious virus particles per 106 mononuclear cells from peripheral blood and lymph nodes had delayed disease onset. All macaques that survived beyond 18 months had measurable Gag-specific CD8+ cytotoxic T cells, regardless of treatment. Humoral immunity in survivors beyond 20 weeks was strikingly different in the SIVIG and control groups. Despite a delay in Env-specific binding antibodies, de novo production of neutralizing antibodies was significantly accelerated in SIVIG-treated macaques. Titers of de novo neutralizing antibodies at week 12 were comparable to levels achieved in controls only by week 32 or later. Acceleration of de novo simian immunodeficiency virus immunity in the presence of passively transferred neutralizing antibodies is a novel finding with implications for postexposure prophylaxis and vaccines.",
author = "Nancy Haigwood and Montefiori, {David C.} and Sutton, {William F.} and Janela McClure and Watson, {Andrew J.} and Gerald Voss and Hirsch, {Vanessa M.} and Richardson, {Barbra A.} and Letvin, {Norman L.} and Hu, {Shiu Lok} and Johnson, {Philip R.}",
year = "2004",
month = "6",
doi = "10.1128/JVI.78.11.5983-5995.2004",
language = "English (US)",
volume = "78",
pages = "5983--5995",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "11",

}

TY - JOUR

T1 - Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies

AU - Haigwood, Nancy

AU - Montefiori, David C.

AU - Sutton, William F.

AU - McClure, Janela

AU - Watson, Andrew J.

AU - Voss, Gerald

AU - Hirsch, Vanessa M.

AU - Richardson, Barbra A.

AU - Letvin, Norman L.

AU - Hu, Shiu Lok

AU - Johnson, Philip R.

PY - 2004/6

Y1 - 2004/6

N2 - Passively transferred neutralizing antibodies can block lentivirus infection, but their role in postexposure prophylaxis is poorly understood. In this nonhuman-primate study, the effects of short-term antibody therapy on 5-year disease progression, virus load, and host immunity were explored. We reported previously that postinfection passive treatment with polyclonal immune globulin with high neutralizing titers against SIVsmE660 (SIVIG) significantly improved the 67-week health of SIVsmE660-infected Macaca mulatta macaques. Four of six treated macaques maintained low or undetectable levels of virus in plasma, compared with one of ten controls, while two rapid progressors controlled viremia only as long as the SIVIG was present. SIVIG treatment delayed the de novo production of envelope (Env)-specific antibodies by 8 weeks (13). We show here that differences in disease progression were also significant at 5 years postinfection, excluding rapid progressors (P = 0.05). Macaques that maintained ≪103 virus particles per ml of plasma and ≪30 infectious virus particles per 106 mononuclear cells from peripheral blood and lymph nodes had delayed disease onset. All macaques that survived beyond 18 months had measurable Gag-specific CD8+ cytotoxic T cells, regardless of treatment. Humoral immunity in survivors beyond 20 weeks was strikingly different in the SIVIG and control groups. Despite a delay in Env-specific binding antibodies, de novo production of neutralizing antibodies was significantly accelerated in SIVIG-treated macaques. Titers of de novo neutralizing antibodies at week 12 were comparable to levels achieved in controls only by week 32 or later. Acceleration of de novo simian immunodeficiency virus immunity in the presence of passively transferred neutralizing antibodies is a novel finding with implications for postexposure prophylaxis and vaccines.

AB - Passively transferred neutralizing antibodies can block lentivirus infection, but their role in postexposure prophylaxis is poorly understood. In this nonhuman-primate study, the effects of short-term antibody therapy on 5-year disease progression, virus load, and host immunity were explored. We reported previously that postinfection passive treatment with polyclonal immune globulin with high neutralizing titers against SIVsmE660 (SIVIG) significantly improved the 67-week health of SIVsmE660-infected Macaca mulatta macaques. Four of six treated macaques maintained low or undetectable levels of virus in plasma, compared with one of ten controls, while two rapid progressors controlled viremia only as long as the SIVIG was present. SIVIG treatment delayed the de novo production of envelope (Env)-specific antibodies by 8 weeks (13). We show here that differences in disease progression were also significant at 5 years postinfection, excluding rapid progressors (P = 0.05). Macaques that maintained ≪103 virus particles per ml of plasma and ≪30 infectious virus particles per 106 mononuclear cells from peripheral blood and lymph nodes had delayed disease onset. All macaques that survived beyond 18 months had measurable Gag-specific CD8+ cytotoxic T cells, regardless of treatment. Humoral immunity in survivors beyond 20 weeks was strikingly different in the SIVIG and control groups. Despite a delay in Env-specific binding antibodies, de novo production of neutralizing antibodies was significantly accelerated in SIVIG-treated macaques. Titers of de novo neutralizing antibodies at week 12 were comparable to levels achieved in controls only by week 32 or later. Acceleration of de novo simian immunodeficiency virus immunity in the presence of passively transferred neutralizing antibodies is a novel finding with implications for postexposure prophylaxis and vaccines.

UR - http://www.scopus.com/inward/record.url?scp=2442689092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442689092&partnerID=8YFLogxK

U2 - 10.1128/JVI.78.11.5983-5995.2004

DO - 10.1128/JVI.78.11.5983-5995.2004

M3 - Article

VL - 78

SP - 5983

EP - 5995

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 11

ER -